Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Ferring Pharmaceuticals announced strong performance results for 2024, with one part of the announcement standing out as ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes. While supply chain interruptions ...

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients ...

Pooja Lal, VP of strategy and commercial content at Veeva Systems, spoke with Pharmaceutical Executive about some of the ways ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...